Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
2000 1
2002 1
2003 3
2004 2
2005 1
2006 3
2007 2
2008 2
2009 3
2010 12
2011 8
2012 6
2013 3
2014 5
2015 9
2016 3
2017 3
2018 6
2019 7
2020 8
2021 3
2022 3
2024 4
2025 8
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Schmid P; KEYNOTE-355 Investigators. Cortes J, et al. Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9. Lancet. 2020. PMID: 33278935 Clinical Trial.
BACKGROUND: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative breast cancer. We aimed to examine whether the addition of pembrolizumab would enhance the antitumour activity of chemotherapy in pati …
BACKGROUND: Pembrolizumab monotherapy showed durable antitumour activity and manageable safety in patients with metastatic triple-negative b …
Voice for Vesna.
Marusić A. Marusić A. Croat Med J. 2011 Apr 15;52(2):214. doi: 10.3325/cmj.2011.52.214. Croat Med J. 2011. PMID: 21495206 Free PMC article. No abstract available.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2025.
Park-Simon TW, Müller V, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer JU, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf AD, Heil J, Hörner-Rieber J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reimer T, Reinisch M, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, Tina van Mackelenbergh M, Witzel I, Wöckel A, Wuerstlein R, Janni W, Thill M. Park-Simon TW, et al. Breast Care (Basel). 2025 Mar 8:1-19. doi: 10.1159/000545019. Online ahead of print. Breast Care (Basel). 2025. PMID: 40236659 Free PMC article. Review.
The Breast Committee of the Arbeitsgemeinschaft Gynakologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with early breast cancer....
The Breast Committee of the Arbeitsgemeinschaft Gynakologische Onkologie (German Gynecological Oncology Group, AGO) presents the 2025 update …
HMGA2 overexpression with specific chromosomal abnormalities predominate in CALR and ASXL1 mutated myelofibrosis.
Handa S, Schaniel C, Tripodi J, Ahire D, Mia MB, Klingborg S, Tremblay D, Marcellino BK, Hoffman R, Najfeld V. Handa S, et al. Leukemia. 2025 Mar;39(3):663-674. doi: 10.1038/s41375-024-02496-0. Epub 2024 Dec 23. Leukemia. 2025. PMID: 39715853 Free PMC article.
Although multiple genetic events are thought to play a role in promoting progression of the myeloproliferative neoplasms (MPN), the individual events that are associated with the development of more aggressive disease phenotypes remain poorly defined. ...
Although multiple genetic events are thought to play a role in promoting progression of the myeloproliferative neoplasms (MPN), the i …
Overview of Cadmium Thyroid Disrupting Effects and Mechanisms.
Buha A, Matovic V, Antonijevic B, Bulat Z, Curcic M, Renieri EA, Tsatsakis AM, Schweitzer A, Wallace D. Buha A, et al. Int J Mol Sci. 2018 May 17;19(5):1501. doi: 10.3390/ijms19051501. Int J Mol Sci. 2018. PMID: 29772829 Free PMC article. Review.
AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2025.
Thill M, Janni W, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, Bjelic-Radisic V, Blohmer J, Budach W, Dall P, Ditsch N, Fallenberg EM, Fasching PA, Fehm T, Friedrich M, Gerber B, Gluz O, Harbeck N, Hartkopf A, Heil J, Hörner-Rieber J, Huober J, Kreipe HH, Krug D, Kühn T, Kümmel S, Loibl S, Lüftner D, Lux MP, Maass N, Mundhenke C, Reinisch M, Reimer T, Rhiem K, Rody A, Schmidt M, Schneeweiss A, Schütz F, Sinn HP, Solbach C, Solomayer EF, Stickeler E, Thomssen C, Untch M, van Mackelenbergh M, Witzel I, Wöckel A, Würstlein R, Müller V, Park-Simon TW. Thill M, et al. Breast Care (Basel). 2025 Mar 8:1-12. doi: 10.1159/000545018. Online ahead of print. Breast Care (Basel). 2025. PMID: 40331128 Free PMC article. Review.
The Breast Committee of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO; German Gynecological Oncology Group) presents the 2025 update of the evidence-based recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer …
The Breast Committee of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO; German Gynecological Oncology Group) presents the 2025 update …
Everything for her!
Andrijević-Matovac V. Andrijević-Matovac V. Croat Med J. 2011 Feb;52(1):89-90. doi: 10.3325/cmj.2011.52.89. Croat Med J. 2011. PMID: 21328726 Free PMC article. No abstract available.
[Hormonal contraception and breast cancer risk].
Bjelic-Radisic V, Petru E. Bjelic-Radisic V, et al. Wien Med Wochenschr. 2010 Nov;160(19-20):483-6. doi: 10.1007/s10354-010-0807-0. Epub 2010 Aug 16. Wien Med Wochenschr. 2010. PMID: 20714815 Review. German.
The largest meta-analysis comprised a total of 54 epidemiologic studies (Collaborative Group on Hormonal Factors in Breast Cancer) and included 53,297 women with breast cancer and 100,239 controls. Women currently using hormonal contraceptives had a modestly elevate …
The largest meta-analysis comprised a total of 54 epidemiologic studies (Collaborative Group on Hormonal Factors in Breast Cancer) an …
A Novel t(1;9)(p36;p24.1) JAK2 Translocation and Review of the Literature.
Levavi H, Tripodi J, Marcellino B, Mascarenhas J, Jones AV, Cross NCP, Gruenstein D, Najfeld V. Levavi H, et al. Acta Haematol. 2019;142(2):105-112. doi: 10.1159/000498945. Epub 2019 May 7. Acta Haematol. 2019. PMID: 31063994 Review.
The JAK2V617F point mutation has been implicated in the pathogenesis of the vast majority of myeloproliferative neoplasms (MPNs), but translocations involving JAK2 have increasingly been identified in patients with JAK2V617F-negativeMPNs. ...
The JAK2V617F point mutation has been implicated in the pathogenesis of the vast majority of myeloproliferative neoplasms (MPNs), but …
Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial.
Banys-Paluchowski M, Hartmann S, Basali T, Gasparri ML, de Boniface J, Gentilini OD, Cakmak GK, Ditsch N, Stickeler E, Schlichting E, Rubio I, Peintinger F, Untch M, Mau C, Federspiel FK, Bucher S, Ramaker K, Paluchowski P, Bauer L, Riemer S, Langanke D, Leuf TD, Schnabel J, von Abel E, Solbach C, Ovalle SC, Hilmer K, Bjelic-Radisic V, Stahl N, Sanchez-Mendez JI, Hagen V, Hansen MH, Krawczyk N, Sezen BA, Jursik K, Thill M, Kolberg HC, Reimer T, Ruf F, Wihlfahrt K, Rief A, Berger T, Schmidt E, Tauber N, Fröhlich S, Kühn T. Banys-Paluchowski M, et al. Breast Cancer Res Treat. 2025 May;211(1):203-211. doi: 10.1007/s10549-025-07635-4. Epub 2025 Feb 20. Breast Cancer Res Treat. 2025. PMID: 39976867
Eligible patients have cT1-4c cN + breast cancer and receive neoadjuvant chemotherapy. Patients are followed up for 5 years. In the present subgroup analysis, only patients with a TLN marked by a radar reflector were included. ...CONCLUSION: To the best of our knowledge, t …
Eligible patients have cT1-4c cN + breast cancer and receive neoadjuvant chemotherapy. Patients are followed up for 5 years. In the p …
93 results